Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC40 (denifanstat) in moderate to severe acne vulgaris – phase III
ChiCTR2500111094Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing ASC40 (denifanstat) 50 mg once daily with ASC40 placebo once daily (2 arms). Primary endpoints: Investigator-assessed treatment success (IGA), Percentage change from baseline in total lesion count and 1 more. Started Oct 2025; status: completed.
02
Drugs
denifanstat
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2500111094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111094.